Cephalon acquires biotechnology company, Ception Therapeutics

NewsGuard 100/100 Score
Apr 6 2010

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has completed its previously announced acquisition of biotechnology company Ception Therapeutics, Inc. and that Ception is now a wholly-owned subsidiary of Cephalon.

Cephalon Chairman and CEO Frank Baldino Jr., Ph.D., said "We are fortunate to have the opportunity to advance CINQUIL™ (reslizumab) into Phase III studies for patients with eosinophilic asthma.  CINQUIL, in addition to our other biologics, peptides and small molecule compounds, provides Cephalon with a robust pipeline of opportunities to bring new therapies to patients over the next several years."

Cephalon has six biologics in its pipeline focused on both inflammatory diseases and cancer.  To view the full pipeline, please visit our website at http://www.cephalon.com/our-science/pipeline.shtml

Source:

 Cephalon, Inc.

Posted in:

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

UNIGE's synthetic anticoagulant provides reliable alternative to heparin
Study reveals inflammation's role in long COVID's lingering effects
Insilico Medicine's AI-designed drug ISM3412 receives FDA IND approval
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy
New protein-based micromaterials developed for targeted cancer therapy
Sino Biological finalizes the acquisition of SignalChem Biotech, strengthening global presence and expanding product portfolio
Vaccines targeting chronic diseases show promise in combatting age-related conditions
Neurolentech signs technology access partnership with Kaerus Bioscience to advance neurodevelopmental disorder research

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
From farm to pharmacy: Transgenic cow milk as a new source of human insulin